How to Read Blood Test Results: Optimal vs Normal Ranges Explained

Standard laboratory reference ranges are defined statistically, not clinically. Most labs establish their ranges by testing a large population sample and marking the middle 95% as "normal." The 2.5% at each extreme are flagged as high or low. The critical problem with this approach is that the sampled population includes people who are overweight, sedentary, metabolically compromised, or in the early stages of disease. "Normal" is therefore an average of a largely unhealthy baseline — it tells you whether you resemble the general public, not whether you are healthy.

Consider fasting blood glucose. The standard reference range is 70–99 mg/dL, meaning anyone below 100 receives a clean bill of health. Yet large-scale data from the Whitehall II study and analyses from the American Diabetes Association consistently show that cardiovascular risk begins rising measurably at glucose levels above 85–88 mg/dL, well below the prediabetes threshold of 100 mg/dL. The functional or optimal range for longevity is commonly cited as 72–88 mg/dL — a significantly narrower window that the standard range entirely obscures.

TSH (thyroid-stimulating hormone) is another vivid example. The conventional range spans 0.4–4.0 mIU/L, a tenfold difference between floor and ceiling. Research published in the Journal of Clinical Endocrinology and Metabolism suggests that TSH values above 2.0 mIU/L may be associated with subclinical hypothyroid symptoms in some individuals, and longevity-focused clinicians typically target 1.0–2.0 mIU/L. A patient sitting at TSH 3.5 will pass a standard screen yet may experience fatigue, weight gain, and cognitive fog attributable to suboptimal thyroid function. The conventional range was never designed to capture this nuance — it was designed to catch Hashimoto's and Graves' disease, not to fine-tune your energy levels.

The practical takeaway is that receiving a result marked "within range" from your lab printout does not mean your biomarker level is optimal. It means it is not in the bottom or top 2.5% of whoever that lab happened to test. Understanding this distinction is the foundational step in using blood tests as a genuine health optimisation tool rather than a disease-exclusion checklist. Learn more about how functional medicine lab testing reframes this approach.

A truly comprehensive longevity panel goes well beyond the basic metabolic panel most GPs order at annual check-ups. The Comprehensive Metabolic Panel (CMP) — which measures glucose, electrolytes, kidney function (BUN, creatinine, eGFR), and liver enzymes (ALT, AST, ALP, bilirubin) — forms the foundation. Chronically elevated ALT even within the normal range (the optimal threshold is below 25 U/L for women and 30 U/L for men, not the standard 56 U/L) is an early sign of hepatic fat accumulation.

The lipid panel deserves a significant upgrade beyond total cholesterol and basic LDL. ApoB, which measures the total number of atherogenic lipoprotein particles rather than their cholesterol content, is now considered by leading cardiologists including Peter Attia and the European Society of Cardiology guidelines as the superior cardiovascular risk marker. An ApoB below 80 mg/dL is generally considered optimal; the standard reference range goes up to 100–130 mg/dL, a range associated with meaningfully elevated atherosclerotic risk.

Hormonal panels reveal the pace of biological aging in ways no other biomarker category can. Testosterone (total and free), DHEA-S, IGF-1, and cortisol collectively map the anabolic-catabolic balance. IGF-1 in particular is a proxy for growth hormone activity; both very low and very high levels are problematic — the sweet spot for longevity is roughly the 50th–75th percentile for your age and sex. A Complete Blood Count (CBC) with differential assesses red blood cell quality (MCV, MCHC), immune cell ratios (neutrophil-to-lymphocyte ratio above 3 predicts increased mortality risk), and platelet function.

Nutritional markers including 25-OH Vitamin D, serum B12, red blood cell folate, magnesium (RBC not serum), ferritin, zinc, and omega-3 index round out the picture. Optimal vitamin D for longevity is 50–80 ng/mL, not the standard lower bound of 20 ng/mL. Ferritin is dual-natured: too low impairs energy and cognition; too high (above 150 ng/mL in men or postmenopausal women) functions as a pro-oxidant and inflammatory marker. Tracking these with the understanding that the optimal window is far narrower than standard ranges is what transforms a routine blood draw into a meaningful longevity tool. Explore how AI-powered biological age blood tests synthesise these markers into a single aging score.

Total cholesterol as a cardiovascular risk predictor is remarkably imprecise. A 2016 meta-analysis in the BMJ Open journal found that in individuals over 60, high total cholesterol was associated with lower, not higher, cardiovascular mortality. The reason is that total cholesterol conflates particles with vastly different risk profiles: protective large HDL particles, small dense LDL particles that penetrate the arterial wall, and large buoyant LDL that are relatively inert. Treating the sum of these as a single number obscures the information that actually matters.

ApoB is currently the most predictive single lipid biomarker available. Every atherogenic particle — LDL, VLDL, IDL, Lp(a) — carries exactly one ApoB molecule. Therefore, ApoB directly counts the number of particles capable of lodging in arterial walls and initiating atherosclerotic plaques. The INTERHEART study, which enrolled over 27,000 participants across 52 countries, found that the ApoB-to-ApoA1 ratio was a stronger predictor of myocardial infarction than any other lipid metric. An optimal ApoB is below 80 mg/dL for average-risk individuals and below 60 mg/dL for those with established cardiovascular disease or diabetes.

LDL-C (the standard LDL cholesterol number on your report) measures the cholesterol content inside LDL particles — not the number of particles. Two people can have identical LDL-C of 100 mg/dL but one may have twice as many particles as the other if their particles are smaller and denser. LDL particle number (LDL-P) measured by NMR spectroscopy or ApoB captures this. Triglycerides are a separate but important signal: optimal levels are below 80 mg/dL (not the standard threshold of 150 mg/dL), and elevated triglycerides in the context of lower HDL is a classic presentation of metabolic syndrome and insulin resistance.

Lp(a), or lipoprotein(a), is a genetically determined particle that approximately 20% of the population carry at elevated levels. It is independent of diet and exercise — no lifestyle intervention meaningfully lowers it — and levels above 50 mg/dL (or 125 nmol/L) confer a significantly elevated risk of both cardiovascular disease and aortic stenosis. Because it is largely genetic, Lp(a) only needs to be measured once in a lifetime. If you have never had it tested, it is the single most important "upgrade" test to request from your doctor, as it can substantially reframe your true cardiovascular risk picture.

High-sensitivity C-reactive protein (hs-CRP) is the most widely validated blood marker of systemic inflammation. Unlike standard CRP (which only detects acute, severe inflammation), hs-CRP can identify low-grade chronic inflammation in the 0.5–3.0 mg/L range. The JUPITER trial, a landmark randomised controlled trial of over 17,000 participants, demonstrated that people with normal LDL but elevated hs-CRP above 2.0 mg/L had significantly elevated cardiovascular event rates — and that reducing inflammation (with statin therapy in that trial) cut event rates by 44%. The functional optimal for hs-CRP is below 0.5 mg/L. Levels above 1.0 mg/L signal meaningful inflammatory burden; above 3.0 mg/L is considered high cardiovascular risk.

Homocysteine is an amino acid produced during methionine metabolism, and elevated levels reflect impaired methylation — the cellular process responsible for DNA repair, detoxification, and neurotransmitter production. Optimal homocysteine is below 8 μmol/L; the standard upper reference range is typically 15 μmol/L, a level associated in Framingham Heart Study data with a doubling of stroke risk. Elevated homocysteine is largely correctable with adequate B12, folate, and B6, making it one of the most actionable biomarkers in a longevity panel. Testing it also illuminates whether someone has the MTHFR polymorphism, which impairs folate conversion and affects roughly 10–15% of the population.

HbA1c measures the average blood glucose over the preceding 90 days by quantifying the proportion of haemoglobin that has been glycated. The standard threshold for diabetes is 6.5% and for prediabetes 5.7–6.4%. But research from the Atherosclerosis Risk in Communities (ARIC) study found that mortality risk begins increasing at HbA1c above 5.4%. Optimal for longevity is 4.8–5.2%. Fasting insulin is an even earlier warning signal — insulin resistance typically develops 10–15 years before HbA1c or fasting glucose become abnormal. An optimal fasting insulin is below 6 μIU/mL; the standard upper limit is often cited as 25 μIU/mL. HOMA-IR (calculated as fasting insulin × fasting glucose ÷ 405) is a standardised index of insulin resistance; a score below 1.0 is optimal, and above 2.0 suggests meaningful resistance. Discover how functional medicine lab testing uses these markers to identify metabolic dysfunction years before diagnosis.

Testing frequency should be calibrated to your goals, health status, and which interventions you are actively making. For healthy adults over 30 who are not currently optimising any specific biomarker, an annual comprehensive panel is the minimum reasonable standard. This panel should go beyond the basic CBC and metabolic panel to include fasting insulin, hs-CRP, HbA1c, ApoB, vitamin D, and thyroid (TSH plus free T3 and free T4). A single annual snapshot gives you a trend line when repeated year over year and flags emerging issues that a disease-only screening would miss for another decade.

If you are actively optimising health — adjusting diet, exercise, supplementation, sleep, or starting a new medication — quarterly biomarker tracking becomes valuable. Many markers respond to lifestyle changes within 8–12 weeks: hs-CRP can drop substantially with anti-inflammatory dietary changes; fasting insulin often improves markedly with low-carbohydrate or time-restricted eating protocols within 6–8 weeks; HbA1c reflects the prior 90-day average and is meaningfully trackable quarterly. Checking relevant markers before and 12 weeks after an intervention tells you whether it is actually working for your individual biology, as opposed to relying on population-average trial data.

Certain situations warrant specific and more frequent testing beyond annual or quarterly schedules. Starting a new medication that affects liver function, kidney function, lipids, or blood counts typically warrants a follow-up panel at 4–8 weeks. Significant weight change (greater than 5–10% body weight), major dietary shifts, pregnancy or postpartum, or a new diagnosis all warrant targeted retesting. At-home blood testing services including Function Health, Marek Health, and Ulta Lab Tests have made self-directed testing increasingly accessible, allowing you to order a comprehensive panel without waiting for a GP referral and often at significantly lower cost than through insurance billing.

Most GPs are trained to interpret blood results through the lens of disease detection, not health optimisation. When a result is within the standard range, the clinical response is typically "no action required." If you want to use blood tests for longevity and performance optimisation, you will need to take a more active role in the conversation. The most effective approach is to come to appointments with specific questions and data: "My fasting insulin is 14 μIU/mL — still within range but trending up from 9 two years ago. I'd like to discuss whether this trajectory warrants intervention." This framing demonstrates engagement, provides context, and is harder for a busy clinician to dismiss than a general "I want to optimise my health."

Requesting non-standard tests within a conventional GP setting can be challenging. Many insurers in the US and NHS commissioners in the UK do not fund ApoB, Lp(a), fasting insulin, or homocysteine testing unless a clinical indication exists. The practical workarounds are: asking your GP to add them to an existing blood draw and note clinical indication (for example, "family history of cardiovascular disease" for Lp(a), or "fatigue and weight gain" for extended thyroid panel); using a direct-to-consumer lab service to run the tests independently and bring results to your appointment; or working with a private functional medicine physician who operates outside insurance constraints. Learn more about how your genes affect drug metabolism — a related area where personalised testing is reshaping clinical practice.

Functional medicine and longevity-focused physicians differ from conventional GPs in that they have the training and clinical frameworks to act on biomarkers in the optimal rather than just the pathological range. If your primary care provider is unreceptive to this approach, it may be worth supplementing your conventional care with periodic consultations with a functional medicine MD or DO — not as a replacement for mainstream medicine, but as a complementary layer focused on health span optimisation. Platforms such as Wild Health, Parsley Health, and Cleveland Clinic Functional Medicine offer structured longevity programmes built around repeated blood testing and personalised intervention. The goal is not to treat you according to reference ranges, but to move every modifiable marker to its best value for you specifically — something that requires a practitioner willing to engage with the data at that level of granularity.